版本:
中国

BRIEF-Catalyst Biosciences and ISU Abxis complete dosing of first patient cohort in Hemophilia B clinical trial

June 14 Catalyst Biosciences Inc

* Catalyst Biosciences and ISU Abxis complete dosing of first patient cohort in Hemophilia B clinical trial

* Says plans to have top line data from in Hemophilia B clinical trial by end of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐